Journal: Molecular oncology
Article Title: New retinoblastoma (RB) drug delivery approaches: anti-tumor effect of atrial natriuretic peptide (ANP)-conjugated hyaluronic-acid-coated gold nanoparticles for intraocular treatment of chemoresistant RB.
doi: 10.1002/1878-0261.13587
Figure Lengend Snippet: Fig. 4. Quantification of tumor formation from grafted retinoblastoma (RB) cells after gold nanoparticle treatment in chorioallantoic membrane (CAM) assays. Tumor formation capacity (A, B), CAM tumor weight (B, E) and CAM tumor size (C, F) of etoposide resistant RB cells was quantified after treatment with GNPs, HA-GNPs, ANP, or ANP-HA-GNPs. Upper row (A–C) shows the results for Y79-Etop cells and lower row (D–F) data for WERI-Etop cells. ANP, atrial natriuretic peptide; ANP-HA-GNP, ANP coupled HA-GNPs; ctr, PBS treated; GNP, gold nanoparticles; HA-GNP, hyaluronic acid coupled GNPs. Values are means of three independent experiments SEM. *P < 0.05; **P < 0.01 statistical differences compared to the control group calculated by one-way ANOVA with Newman–Keuls post-test.
Article Snippet: The human retinoblastoma (RB) cell lines Y79 [28] (RRID: CVCL_1893) and WERI [29] (RRID: CVCL_1792), originally purchased from the Leibniz Institute DSMZ (German Collection of Microorganisms and Cell Cultures) were placed to our disposal by H. Stephan along with the RB cell line RB355 [30] (RRID: CVCL_S611), initially provided by K. Heise, and the corresponding etoposide-resistant RB cell lines Y79-Etop, WERI-Etop, and RB355-Etop.
Techniques: Membrane, Control